Clinical Trial Update: A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 study assessing 24-week efficacy, safety, and tolerability of rivastigmine transdermal patch in probable Alzheimer's disease; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Exelon Patch (rivastigmine transdermal patch)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-08-04